The Indian Multiple Sclerosis Drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
India is expected to dominate the market in Asia-Pacific due to changing lifestyle along with increasing prevalence of multiple sclerosis. Multiple sclerosis (MS) is being increasingly diagnosed in India mainly due to increase in the number of practicing neurologists and easy and affordable availability of magnetic resonance imaging (MRI). The crude prevalence of MS in India stands at 8-9 people per. MS can occur at any age but is usually diagnosed between the ages of 20 and 40 years and reported mostly in women (approximately 3 times more often than in men). The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS).
The key factor for growth of Indian multiple sclerosis drugs market is the rise of demand in the market by pharmaceutical and biotechnological companies with surge in research and development activities including various clinical trials for advanced new drugs against MS disease with huge investment. Many pharmaceutical companies are focusing on novel therapies for treating MS. The expected launch of pipeline products along with the proactive government support and recommendations are encouraging factors for many market players across the globe. Also, the growing prevalence of this disease and the awareness programmes launched by the government to teach patients regarding the treatment options available will drive the future growth of the market.